Dr John Moppett talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about how to combine MRD quantitation and genetics in post-remission risk stratification.

Dr Moppett discusses the different markers for ALL with emphasis on minimal residual disease (MRD).

He also explains the complexity behind explaining the prognosis to patients due to it's own complex nature.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.